What Is Mounjaro? Everything You Should Know Before Starting

Mounjaro at a glance:

• Drug class: Dual GIP / GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• FDA approved: 2022
• Route: subcutaneous injection
• Typical frequency: once weekly
• Half-life: approximately 5 days
• Cash price (US): $1,000-$1,100/month without insurance
• Receptor target: GIP and GLP-1 receptors (dual)

Let's cut through the marketing on Mounjaro and look at what the data actually say. Mounjaro is tirzepatide labeled for type 2 diabetes, and the result for users is: a1c reductions of 1.8-2.4% and weight loss of 7-12 kg in surpass trials — outperforming semaglutide head-to-head.

What is Mounjaro?

Mounjaro is tirzepatide labeled for type 2 diabetes. Tirzepatide is the first dual incretin agonist, activating both GIP and GLP-1 receptors. The GIP component appears to enhance both insulin secretion and weight effects beyond GLP-1 alone.

Mounjaro is manufactured by Eli Lilly and is a brand name for the generic compound tirzepatide. Mounjaro was approved by the FDA in 2022. Its approved indications include type 2 diabetes. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class dual gip / glp-1 receptor agonist works by acting at the GIP and GLP-1 receptors (dual). Below we get into specifics.

How Mounjaro Works in the Body

Mounjaro is tirzepatide labeled for type 2 diabetes. Tirzepatide is the first dual incretin agonist, activating both GIP and GLP-1 receptors. The GIP component appears to enhance both insulin secretion and weight effects beyond GLP-1 alone. The receptor target — GIP and GLP-1 receptors (dual) — drives the downstream effects users care about: a1c reductions of 1.8-2.4% and weight loss of 7-12 kg in surpass trials — outperforming semaglutide head-to-head.

The pharmacokinetics matter for daily use. Mounjaro has a half-life of approximately 5 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection, and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how Mounjaro works.

Who Uses Mounjaro?

Mounjaro is most relevant for people whose situation maps to its approved indications: type 2 diabetes. Off-label uses include weight loss (off-label; same molecule is approved as Zepbound for obesity).

People who should avoid Mounjaro include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome

Common and Serious Side Effects

The most commonly reported side effects of Mounjaro include:

• nausea
• diarrhea
• decreased appetite
• vomiting
• constipation
• abdominal pain
• injection-site reactions

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• gallbladder disease
• thyroid C-cell tumors (boxed warning)
• acute kidney injury
• diabetic retinopathy worsening

We have a more detailed breakdown in our Mounjaro side-effects guide.

Mounjaro vs Alternatives

Common alternatives include Ozempic (semaglutide for T2D), Trulicity (dulaglutide, also weekly), and Zepbound (same molecule, weight-loss indication). If you are weighing Mounjaro against another option, our comparison pages include Mounjaro Side Effects: 7 Things to Watch For (and How to Manage Them), Mounjaro Outcomes Decoded: Who Responds Best and Why, Why Mounjaro Costs So Much (and 5 Ways to Pay Less).

Bottom Line

If you're considering Mounjaro, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Multiple randomized controlled trials support its efficacy. If you are considering Mounjaro, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Mounjaro Side Effects: 7 Things to Watch For (and How to Manage Them)
• Mounjaro Outcomes Decoded: Who Responds Best and Why
• Why Mounjaro Costs So Much (and 5 Ways to Pay Less)
• Mounjaro and Weight Loss: What Trials Show vs. Real Life
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.